<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941004-0-00006</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective November 3, 1994; written comments, notice of participation, and request for a hearing by November 3, 1994; data, information, and analyses to justify a hearing by December 5, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=1 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 450</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 94N&hyph;0302]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Antibiotic Drugs; Bleomycin Sulfate <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the antibiotic drug regulations to provide for standards of an antibiotic drug, bleomycin sulfate bulk drug substance. The manufacturer has supplied sufficient data and information to establish its safety and efficacy. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective November 3, 1994; written comments, notice of participation, and request for a hearing by November 3, 1994; data, information, and analyses to justify a hearing by December 5, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> James Timper, Center for Drug Evaluation and Research (HFD&hyph;520), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;6714. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA has evaluated data submitted in  <!-- PJG 0012 frnewline --> accordance with regulations promulgated under section 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357), as amended, with respect to a request for approval to provide for bleomycin sulfate bulk drug substance. The agency has concluded that the data supplied by the manufacturer concerning the antibiotic drug are adequate to establish its safety and efficacy when used as directed in the labeling and that the regulations should be amended in 21 CFR part 450 to provide for the inclusion of accepted standards for this product. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The agency has determined under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Submitting Comments and Filing Objections <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> This final rule announces standards that FDA has accepted in a request for approval of an antibiotic drug. Because this final rule is not controversial and because when effective it provides notice of accepted standards, FDA finds that notice and comment procedure is unnecessary and not in the public interest. This final rule, therefore, is effective on November 3, 1994. However, interested persons may, on or before November 3, 1994, submit comments to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Any person who will be adversely affected by this final rule may file objections to it and request a hearing. Reasonable grounds for the hearing must be shown. Any person who decides to seek a hearing must file (1) on or before November 3, 1994, a written notice of participation and request for a hearing, and (2) on or before December 5, 1994, the data, information, and analyses on which the person relies to justify a hearing, as specified in 21 CFR 314.300. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for a hearing that no genuine and substantial issue of fact precludes the action taken by this order, or if a request for a hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who request(s) the hearing, making findings and conclusions and denying a hearing. All submissions must be filed in three copies, identified with the docket number appearing in the heading of this document and filed with the Dockets Management Branch. <!-- PJG 0012 frnewline --> The procedures and requirements governing this order, a notice of participation and request for a hearing, a submission of data, information, and analyses to justify a hearing, other comments, and grant or denial of a hearing are contained in 21 CFR 314.300. <!-- PJG 0012 frnewline --> All submissions under this order, except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Part 450 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Antibiotics. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 450 is amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 450_ANTITUMOR ANTIBIOTIC DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 450 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 450.10 is added to subpart A to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;450.10  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Bleomycin sulfate.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Bleomycin sulfate is the amorphous sulfate salt of bleomycin. Bleomycin has been separated into several similar glyco-peptide molecules. It is a cream-colored powder that is so purified and dried that:  <!-- PJG 0012 frnewline --> (i) Its potency is not less than 1.5 units and not more than 2.0 units of bleomycin per milligram.  <!-- PJG 0012 frnewline --> (ii) It contains no depressor substances. <!-- PJG 0012 frnewline --> (iii) Its loss on drying is not more than 6.0 percent. <!-- PJG 0012 frnewline --> (iv) Its pH in an aqueous solution containing 10 units per milliliter is not less than 4.5 and not more than 6.0. <!-- PJG 0012 frnewline --> (v) Its copper content is not greater than 0.1 percent. <!-- PJG 0012 frnewline --> (vi) Its content of various bleomycins is as follows: Bleomycin A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is not less than 55 percent and not more than 70 percent; bleomycin B <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is not less than 25 percent and not more than 32 percent; bleomycin B <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 4 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is not more than 1 percent. Bleomycins A <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and B <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=2 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  should comprise not less than 85 percent of the total bleomycins. <!-- PJG 0012 frnewline --> (vii) It passes the identity test. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5(b) of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain:  <!-- PJG 0012 frnewline --> (i) Results of tests and assays on the batch for potency, depressor substances, loss on drying, pH, copper, content of various bleomycins, and identity. <!-- PJG 0012 frnewline --> (ii) Samples required: For all tests: A minimum of 20 immediate containers. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Potency <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.105 of this chapter, preparing the sample for assay as follows: Dissolve an accurately weighed sample in sufficient 0.1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> M <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  potassium phosphate buffer, pH 7.0 (solution 16), to provide a stock solution of convenient concentration. Dilute the sample thus obtained with solution 16 to provide a stock solution of convenient concentration. Further dilute an aliquot of the stock solution with solution 16 to the reference concentration of 0.04 unit of activity per milliliter (estimated). <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Depressor substances <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.35 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Loss on drying <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.200(a) of this chapter, using the total contents of two or three vials. <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> pH <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.2 <!-- PJG 0012 frnewline --> 02 of this chapter, using an aqueous solution containing 10 units per milliliter. <!-- PJG 0012 frnewline --> (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Copper content <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Reagents <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Dissolve 10 milligrams of zinc dibenzyldithiocarbamate in 100 milliliters of carbon tetrachloride. <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of standard copper solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Accurately weigh 1.965 grams of cupric sulfate pentahydrate and transfer to a 1-liter volumetric flask. Dissolve the material in 0.1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid, dilute to volume with 0.1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid, and mix well. Transfer 3 milliliters of this stock solution to a 1-liter volumetric flask, dilute to volume with 0.1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid, and mix well. This standard copper solution contains 0.0015 milligram of copper per milliliter. Transfer 10 milliliters of the standard copper solution to a 60-milliliter separatory funnel. <!-- PJG 0012 frnewline --> (iii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of the sample <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Accurately weigh approximately 15 milligrams of sample into a 60-millilter separatory funnel. Dissolve the sample in 10 milliliters of 0.1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> N <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  hydrochloric acid. <!-- PJG 0012 frnewline --> (iv)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Procedure <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . To the separatory funnels containing the sample solution and standard copper solution, add 10 milliliters of the zinc dibenzyldithiocarbamate solution and shake the funnels vigorously for 1 minute. Allow the phases to separate. Filter the carbon tetrachloride phase (lower phase) through 1 gram of anhydrous sodium sulfate to remove excess water. Using a suitable spectrophotometer equipped with 1-centimeter cells, and carbon tetrachloride as a blank, measure the absorbance of the standard copper solution and the sample solution at 435 nanometers. Calculate the percent copper as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),tp0,g1,t1,aw,s50,r3,r75  -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Percent copper  <!-- PJG 007 0150 intable --> 1=  <!-- PJG 007 0150 intable --> 1Absorbance of sample solution X 1.5  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2Absorbance of standard copper solution X Sample weight in milligrams  <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> (6)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Content of various bleomycin fractions <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.339 of this chapter. <!-- PJG 0012 frnewline --> (7)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Identity test <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.211 of this chapter, using the method described in paragraph (b)(1) of that section, using a 1 percent mixture. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: September 27, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> David B. Barr, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Office of Compliance, Center for Drug Evaluation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;24543 Filed 10&hyph;3&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            